Currently, the company is evaluating the efficacy and safety of SD-809 to treat chorea associated with this disorder in a Phase III registration clinical trial and is scheduled
Myalept is an orphan product indicated to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy, a rare disease associated with the loss of
MM-141 is a tetravalent bispecific antibody that blocks tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3), which activate a major cellular signaling pathway that
DRP, which is a highly validated systems-biology-based biomarker platform, has been developed by MPI and it is useful for identifying likely responding patients for targeted enrollment of cancer
Mepolizumab is delivered in a 100mg dose via subcutaneous injection every four weeks. Eosinophilic asthma is identified by a blood eosinophil count of at least 150 cells per
ADXS31-142 is the company’s lead Lm-LLO immunotherapy designed to specifically target prostate-specific antigen (PSA). Following FDA’s acceptance of the IND submission, the proposed Phase I/II protocol will assess
The approval of this combination regimen is for patients whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. The FDA approval is based on data
The new 92-bed treatment facility will be jointly operated by the UK’s Department for International Development (DfID) and charity organisation, Save the Children. The centre includes an 80-bed
Multiple sclerosis is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system. The EMPIRE trial is designed to evaluate the efficacy, safety, tolerability and pharmacokinetics
A total of 150 patients will be enrolled in the randomized, double-blind trial, which is designed to evaluate RUT58-60’s safety, tolerability and potential efficacy for use as an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.